The biggest obstacle for med-tech giant Medtronic (MDT) today is not its competition nor the still-sleepy markets for medical procedures. Instead, the biggest problem Medtronic has is a market/investor base that seems unwilling to accept the company for what it is. Medtronic came in shy of the more robust growth expectations this quarter, but even modest long-term growth projections suggest these shares are undervalued today.
Fiscal Q3 Comes In Evenly Light
At least a few sell-side analysts had been trying to make the case that this would be the quarter where Medtronic would make the turn and re-establish good mid-single digit organic growth credentials. That didn't come to pass, though, as Medtronic had a pretty "meh" quarter across...
Only subscribers can access this article, which is part of the PRO research library covering 3,760 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: